Mechanistic study of SGLT2 inhibitor in the treatment of diabetic kidney disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062178

Enrollment

Unknown

Registered

2022-07-27

Start date

2022-08-01

Completion date

Unknown

Last updated

2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Kidney Disease

Interventions

control group:Received a stable dose of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)

trial group:Received canagliflozin (100 mg, once daily)

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged >= 30 years and clinically diagnosed type 2 diabetes; 2.6.5% <= HbA1c <= 12%; 3.30 <= eGFR < 90 ml/min/1.73m2 (calculated using CKD-EPI formula); 4.300 < UACR <= 5000 mg/g.

Exclusion criteria

Exclusion criteria: 1.Patients with history of diabetic ketoacidosis or type 1 diabetes; 2.Patients with hereditary glucose-galactose malabsorption or history of primary renal grape diabetes; 3.Patients with serious cardiovascular and cerebrovascular diseases and liver diseases; 4.patients with kidney disease who need to receive immunosuppressive therapy; 5.Kidney transplant patients or patients with dialysis treatment; 6.Allergic or intolerant to SGLT2i.

Design outcomes

Primary

Measure	Time frame
Glycosylated Hemoglobin;Urinary Albumin-to-Creatinine Ratio;Complete Blood Count;Erythropoietin;	—

Countries

China

Contacts

Public ContactQin Guijun

the First Affiliated Hospital of Zhengzhou University

hyqingj@zzu.edu.cn+86 135 9886 0123

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026